nach oben

Clinical and Translational Oncology

Erschienen in:

11.04.2023 | REVIEW ARTICLE

The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer

verfasst von: Jia Nie, Di Wang, MingJian Li

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

The development of cancers is aided by the accumulation of myeloid-derived suppressor cells (MDSCs) within tumors, which are highly effective at suppressing anti-tumor immune responses. Direct cell-to-cell interaction and the production of immunosuppressive mediators have both been proposed as pathways for MDSC-mediated suppression of anti-tumor immune responses. The majority of current cancer treatments focus on altering the development and activity of MDSCs so that they have more of an immunogenic character. Autophagy is a catabolic system that contributes to the breakdown of damaged intracellular material and the recycling of metabolites. However, depending on the stage of tumor growth, autophagy can play both a prophylactic and a therapeutic function in carcinogenesis. However, several indirect lines of research have indicated that autophagy is a significant regulator of MDSC activity. The purpose of this work was to outline the interactions between MDSC and autophagy in cancer.

Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci. 2011;108(41):17111–6.PubMedPubMedCentralCrossRef

Hao Z, Li R, Wang Y, Li S, Hong Z, Han Z. Landscape of Myeloid-derived suppressor cell in tumor immunotherapy. Biomarker Res. 2021;9(1):77.CrossRef

Tian Y, Xiao H, Yang Y, Zhang P, Yuan J, Zhang W, et al. Crosstalk between 5-methylcytosine and N6-methyladenosine machinery defines disease progression, therapeutic response and pharmacogenomic landscape in hepatocellular carcinoma. Mol Cancer. 2023;22(1):1–25.CrossRef

Yu Y, Wang L, Ni S, Li D, Liu J, Chu HY, et al. Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nat Commun. 2022;13(1):4241.PubMedPubMedCentralCrossRef

An X, Li N, Zhang S, Han Y, Zhang Q. Integration of proteome and metabolome profiling to reveal heat stress response and tolerance mechanisms of Serratia sp. AXJ-M for the bioremediation of papermaking black liquor. J Hazardous Mater. 2023. https://doi.org/10.1016/j.jhazmat.2023.131092.CrossRef

Parker KH, Horn LA, Ostrand-Rosenberg S. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. J Leucocyte Biol. 2016;100(3):463–70.CrossRef

Samimi Z, Kardideh B, Zafari P, Bahrehmand F, Roghani SA, Taghadosi M. The impaired gene expression of adenosine monophosphate-activated kinase (AMPK), a key metabolic enzyme in leukocytes of newly diagnosed rheumatoid arthritis patients. Mol Biol Rep. 2019;46:6353–60.PubMedCrossRef

SuiX Z. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. FrontPharmacol. 2018;9:1371.

Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410.PubMedCrossRef

10.

Hu S, Hui Z, Lirussi F, Garrido C, Ye X-Y, Xie T. Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present). Expert Opin Ther Pat. 2021;31(5):435–52.PubMedCrossRef

11.

Lou J-S, Zhao L-P, Huang Z-H, Chen X-Y, Xu J-T, Tai WC-S, et al. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer. Phytomedicine. 2021. https://doi.org/10.1016/j.phymed.2020.153370.CrossRefPubMed

12.

White E. The role for autophagy in cancer. J Clin Investig. 2015;125(1):42–6.PubMedPubMedCentralCrossRef

13.

Vafaei S, Fattahi F, Sahlolbei M, Kiani J, Yazdanpanah A, Madjd Z. Dynamic signature of tRNA-derived small RNAs in cancer pathogenesis as a promising valuable approach. Critical Rev Eukaryotic Gene Exp. 2020. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2020035372.CrossRef

14.

Liu S, Li Q, Chen K, Zhang Q, Li G, Zhuo L, et al. The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression. Biomed Pharmacother. 2020;127: 110098.PubMedCrossRef

15.

Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6(4):463–77.PubMedCrossRef

16.

Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7(1):12150.PubMedPubMedCentralCrossRef

17.

Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P, Bronte V. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett. 2008;267(2):216–25.PubMedCrossRef

18.

Tcyganov E, Mastio J, Chen E, Gabrilovich DI. Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018;51:76–82.PubMedPubMedCentralCrossRef

19.

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319(1):47–65.PubMedCrossRef

20.

Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.PubMedPubMedCentralCrossRef

21.

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828–35.PubMedPubMedCentralCrossRef

22.

Ashjari D, Karamali N, Rajabinejad M, Hassani SS, Hezarkhani LA, Afshari D, et al. The axis of long non-coding RNA MALAT1/miR-1-3p/CXCR4 is dysregulated in patients with diabetic neuropathy. Heliyon. 2022;8(3): e09178.PubMedPubMedCentralCrossRef

23.

Koike Y, Kanai T, Saeki K, Nakamura Y, Nakano M, Mikami Y, et al. MyD88-dependent interleukin-10 production from regulatory CD11b+ Gr-1high cells suppresses development of acute cerulein pancreatitis in mice. Immunol Lett. 2012;148(2):172–7.PubMedCrossRef

24.

Iranshahi N, Assar S, Amiri SM, Zafari P, Fekri A, Taghadosi M. Decreased gene expression of Epstein-Barr Virus-Induced Gene 3 (EBI-3) may contribute to the pathogenesis of rheumatoid arthritis. Immunol Invest. 2019;48(4):367–77.PubMedCrossRef

25.

Pan P-Y, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Can Res. 2010;70(1):99–108.CrossRef

26.

Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell ActivityRescue of NK Cells by Blocking the Induction of MDSCs. Clin Cancer Res. 2014;20(15):4096–106.PubMedCrossRef

27.

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–90.PubMedPubMedCentralCrossRef

28.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.PubMedCrossRef

29.

Li Y-J, Lei Y-H, Yao N, Wang C-R, Hu N, Ye W-C, et al. Autophagy and multidrug resistance in cancer. Chin J Cancer. 2017;36(1):1–10.CrossRef

30.

Kishi-Itakura C, Koyama-Honda I, Itakura E, Mizushima N. Ultrastructural analysis of autophagosome organization using mammalian autophagy-deficient cells. J Cell Sci. 2014;127(18):4089–102.PubMed

31.

Wang H, Gao Y, Vafaei S, Yu Q, Zhang J, Wang L. A chemoresistance lncRNA signature for recurrence risk stratification of colon cancer patients with chemotherapy. Mole Ther-Nucl Acids. 2022;27:427–38.CrossRef

32.

Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci. 2018;19(11):3466.PubMedPubMedCentralCrossRef

33.

Dasari SK, Bialik S, Levin-Zaidman S, Levin-Salomon V, Merrill AH, Futerman AH, et al. Signalome-wide RNAi screen identifies GBA1 as a positive mediator of autophagic cell death. Cell Death Differ. 2017;24(7):1288–302.PubMedPubMedCentralCrossRef

34.

Dasari SK, Schejter E, Bialik S, Shkedy A, Levin-Salomon V, Levin-Zaidman S, et al. Death by over-eating: The Gaucher disease associated gene GBA1, identified in a screen for mediators of autophagic cell death, is necessary for developmental cell death in Drosophila midgut. Cell Cycle. 2017;16(21):2003–10.PubMedPubMedCentralCrossRef

35.

Deng G, editor Intervention effect of vitamin D intake and serum 25 (OH) D level on ovarian cancer risk. European Journal of Gynaecological Oncology; 2022: Mre Press 14 Robinson Rd# 08–01a Far East Finance, Singapore, Singapore.

36.

Lorin S, Hamaï A, Mehrpour M, Codogno P. Autophagy regulation and its role in cancer. Sem Cancer Biol. 2013. https://doi.org/10.1016/j.semcancer.2013.06.007.CrossRef

37.

Azad MB, Chen Y, Gibson SB. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal. 2009;11(4):777–90.PubMedCrossRef

38.

Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen H-Y, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137(6):1062–75.PubMedPubMedCentralCrossRef

39.

Burada F, Nicoli ER, Ciurea ME, Uscatu DC, Ioana M, Gheonea DI. Autophagy in colorectal cancer: an important switch from physiology to pathology. World J of Gastrointestinal Oncol. 2015;7(11):271.CrossRef

40.

Karami Fath M, Azargoonjahromi A, Soofi A, Almasi F, Hosseinzadeh S, Khalili S, et al. Current understanding of epigenetics role in melanoma treatment and resistance. Cancer Cell Int. 2022;22(1):1–23.CrossRef

41.

Wang H, Fang Z-Z, Zheng Y, Zhou K, Hu C, Krausz KW, et al. Metabolic profiling of praziquantel enantiomers. Biochem Pharmacol. 2014;90(2):166–78.PubMedPubMedCentralCrossRef

42.

Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10.PubMedPubMedCentralCrossRef

43.

Chavez-Dominguez R, Perez-Medina M, Lopez-Gonzalez JS, Galicia-Velasco M, Aguilar-Cazares D. The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity. Front Oncol. 2020;10: 578418.PubMedPubMedCentralCrossRef

44.

Rabbani B, Khorgami M, Dalili M, Zamani N, Mahdieh N, Gollob MH. Novel cases of pediatric sudden cardiac death secondary to TRDN mutations presenting as long QT syndrome at rest and catecholaminergic polymorphic ventricular tachycardia during exercise: The TRDN arrhythmia syndrome. Am J Med Genet A. 2021;185(11):3433–45.PubMedCrossRef

45.

Omidi N, Arabloo J, Rezapour A, Alaeddini F, Bragazzi NL, Pourasghari H, et al. Burden of hypertensive heart disease in Iran during 1990–2017: findings from the Global Burden of Disease study 2017. PLoS ONE. 2021;16(9): e0257617.PubMedPubMedCentralCrossRef

46.

White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401–10.PubMedPubMedCentralCrossRef

47.

Chen H-T, Liu H, Mao M-J, Tan Y, Mo X-Q, Meng X-J, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy. Mol Cancer. 2019;18(1):1–19.PubMedPubMedCentralCrossRef

48.

Sharif T, Martell E, Dai C, Kennedy BE, Murphy P, Clements DR, et al. Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy. 2017;13(2):264–84.PubMedCrossRef

49.

Peng Q, Qin J, Zhang Y, Cheng X, Wang X, Lu W, et al. Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. J Exp Clin Cancer Res. 2017;36(1):1–12.CrossRef

50.

Li L, Pan D, Zhang S, Xie D, Zheng X, Chen H. Autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(11):3402–7.PubMed

51.

Alissafi T, Hatzioannou A, Mintzas K, Barouni RM, Banos A, Sormendi S, et al. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest. 2018;128(9):3840–52.PubMedPubMedCentralCrossRef

52.

Korolchuk VI, Saiki S, Lichtenberg M, Siddiqi FH, Roberts EA, Imarisio S, et al. Lysosomal positioning coordinates cellular nutrient responses. Nat Cell Biol. 2011;13(4):453–60.PubMedPubMedCentralCrossRef

53.

Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21(1):144.PubMedPubMedCentralCrossRef

54.

Bos R, Sherman LA. CD4+ T-Cell Help in the Tumor Milieu Is required for recruitment and cytolytic Function of CD8+ T LymphocytesMechanisms of Tumor-Specific CD4 Help. Can Res. 2010;70(21):8368–77.CrossRef

55.

Nagaraj S, Nelson A, Youn J-i, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4+ T Cells Regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC Class II SignalingMDSC and CD4+ T cells. Can Res. 2012;72(4):928–38.CrossRef

56.

Hu Z, Zhao TV, Huang T, Ohtsuki S, Jin K, Goronzy IN, et al. The transcription factor RFX5 coordinates antigen-presenting function and resistance to nutrient stress in synovial macrophages. Nat Metab. 2022;4(6):759–74.PubMedPubMedCentralCrossRef

57.

Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+ HLA-DR−/low Cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-SignCharacterization of Melanoma CD14+ HLA-DR−/low MDSC. Can Res. 2010;70(11):4335–45.CrossRef

58.

Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Can Res. 2008;68(13):5439–49.CrossRef

59.

Wu JS, Li L, Wang SS, Pang X, Wu JB, Sheng SR, et al. Autophagy is positively associated with the accumulation of myeloid-derived suppressor cells in 4-nitroquinoline-1-oxide-induced oral cancer. Oncol Rep. 2018;40(6):3381–91.PubMedPubMedCentral

60.

Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 2014;41(3):389–401.PubMedPubMedCentralCrossRef

61.

Scherz-Shouval R, Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem Sci. 2011;36(1):30–8.PubMedCrossRef

62.

Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Can Res. 2014;74(20):5723–33.CrossRef

63.

Tang D, Kang R, Livesey KM, Cheh C-W, Farkas A, Loughran P, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010;190(5):881–92.PubMedPubMedCentralCrossRef

64.

Mosaddegh R, Nabi S, Daei S, Mohammadi F, Masoumi G, Vaziri S, et al. Combination of liver enzymes, amylase and abdominal ultrasound tests have acceptable diagnostic values as an alternative test for abdominopelvic CT scan in blunt abdominal trauma. Open Access Emerg Med. 2019. https://doi.org/10.2147/OAEM.S207066.CrossRefPubMedPubMedCentral

65.

Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouysségur J, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol. 2009;29(10):2570–81.PubMedPubMedCentralCrossRef

66.

Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439–53.PubMedPubMedCentralCrossRef

67.

Zhang K, Liang F, Qaria MA, Wang H, Lin M, Zhang F. Roles of 630 nm red light-emitting diode in inhibition of RhoA Signal transduction pathway via reducing plekhg5 expression and alleviation of inflammatory response in macrophages. J Biol Regu Homeostatic Agents. 2022;36(5):1419–26.

68.

Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, et al. Aerobic Glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer. Cell Metab. 2018;28(1):87-103.e6.PubMedPubMedCentralCrossRef

69.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–90.PubMedPubMedCentralCrossRef

70.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134.PubMedPubMedCentralCrossRef

71.

Zou W, Wolchok JD, Chen L. PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Translational Med. 2016. https://doi.org/10.1126/scitranslmed.aad7118.CrossRef

72.

Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, et al. Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clinl Invest. 2021. https://doi.org/10.1172/JCI146832).CrossRef

73.

Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017. https://doi.org/10.1016/j.cell.2017.07.008.CrossRefPubMedPubMedCentral

74.

Miao T, Liu Y, (2022) editors. Clinical study of VBA-based diffusion kurtosis imaging technique on cognitive dysfunction of breast cancer patients undergoing chemotherapy. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY,: MRE PRESS 14 ROBINSON RD# 08–01A FAR EAST FINANCE, SINGAPORE, SINGAPORE.

75.

Wang W, Kryczek I, Dostál L, Lin H, Tan L, Zhao L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016;165(5):1092–105.PubMedPubMedCentralCrossRef

76.

Liu F, Li X, Lu C, Bai A, Bielawski J, Bielawska A, et al. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. Oncotarget. 2016;7(51):83907–25.PubMedPubMedCentralCrossRef

77.

Wang B, Dong G, Zhang Q, Yan F, Li Z, Li C, et al. The inhibitor of autophagy SBI-0206965 aggravates atherosclerosis through decreasing myeloid-derived suppressor cells. Exp Ther Med. 2020;19(2):1370–8.PubMed

78.

Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–68.PubMedPubMedCentralCrossRef

79.

Bergenfelz C, Leandersson K. The generation and identity of human myeloid-derived suppressor cells. Front Oncol. 2020;10:109.PubMedPubMedCentralCrossRef

80.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells Blood. J Am Soc Hematol. 2015;126(13):1621–8.

Titel: The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer
verfasst von: Jia Nie
Di Wang
MingJian Li
Publikationsdatum: 11.04.2023
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 10/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03160-2

Springer Medizin

The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2023

Emerging roles of long non-coding RNA FTX in human disorders

Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy

Remembering Edmund Klein: the Father of Immunotherapy

Advances in the expression and function of Fyn in different human tumors

Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer

Oncogenic roles of GPR176 in breast cancer: a potential marker of aggressiveness and a potential target of gene therapy

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie